GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sionna Therapeutics Inc
The value of Sionna Therapeutics, a privately held biotech company, is determined by its progress in developing a new generation of cystic fibrosis drugs. The potential post-IPO share price will depend on the results of clinical trials and its ability to compete with established market leaders.
Share prices of companies in the market segment - Dna
Sionna, a private biotech developing drugs to treat cystic fibrosis, is valued based on the potential of its scientific platform. We classify it as part of the Dna sector, and the chart below reflects the dynamics of this entire segment, driven by clinical trial news.
Broad Market Index - GURU.Markets
Sionna Therapeutics is a biopharmaceutical company developing drugs to treat cystic fibrosis. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SION - Daily change in the company's share price Sionna Therapeutics Inc
For Sionna Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Dna
Sionna Therapeutics Inc. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with SION's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Sionna Therapeutics is a privately held biopharmaceutical company developing treatments for cystic fibrosis. Its potential IPO will depend heavily on the market's appetite for biotech innovation. The chart below illustrates the general volatility that affects the fate of such companies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sionna Therapeutics Inc
Sionna is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Sionna, a private biotech company, develops drugs to treat cystic fibrosis. Its growth is driven by clinical trial successes. Its valuation reflects investors' confidence in its ability to develop the best therapy for this disease, potentially outperforming the entire pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sionna Therapeutics is privately held and not publicly traded. Its market performance cannot be analyzed. As a biotech focused on treating cystic fibrosis, its value is determined solely by clinical trial results and scientific breakthroughs, not by economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sionna Therapeutics Inc
Sionna, a clinical-stage biotech company specializing in the treatment of cystic fibrosis, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its evaluation.
Monthly dynamics of market capitalization of the market segment - Dna
Cystic fibrosis biotechnology is a highly competitive field, where new drugs could change the standard of care. The dynamics of this sector, as seen in the chart, reflect investor expectations for clinical data. This is the environment in which companies like Sionna Therapeutics are pursuing their developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sionna Therapeutics is an early-stage biotech company. Its shares are steeped in lab data and investor expectations about science. Their value can fluctuate wildly, ignoring macroeconomic events and overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sionna Therapeutics Inc
Short-term price movements of Sionna, a clinical-stage biotech, are entirely dependent on news related to the development of cystic fibrosis drugs. Any research data or news from competitor Vertex Pharma could trigger extreme stock movements.
Weekly dynamics of market capitalization of the market segment - Dna
Sionna Therapeutics shares, like those of the entire cystic fibrosis biotech sector, are heavily dependent on the broader news in this niche. The actions of market leader Vertex Pharma set the tone for everyone. The chart below will show how the startup stacks up against this giant.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Sionna Therapeutics often live in their own world, isolated from broader market fluctuations. The fate of their stocks is determined not by inflation reports, but by clinical trial results. The chart will show how often their stock moves against the broader market tide.
Market capitalization of the company, segment and market as a whole
SION - Market capitalization of the company Sionna Therapeutics Inc
Sionna Therapeutics' market capitalization chart visualizes the hopes of developing a new, more effective treatment for cystic fibrosis. It reflects investors' assessment of the company's scientific potential as it seeks to challenge dominant players. Its speculative dynamics are a classic biotech story of high risk and potentially enormous reward.
SION - Share of the company's market capitalization Sionna Therapeutics Inc within the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing next-generation drugs for the treatment of cystic fibrosis. Its market share is based on the potential of its scientific approach. The chart shows how the market assesses its chances of creating a more effective therapy for a broad group of patients with this disease.
Market capitalization of the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing treatments for cystic fibrosis. The chart below shows the overall value of the DNA analysis sector. Its growth reflects advances in the treatment of genetic diseases. In this area, Sionna strives to offer new, more effective solutions for patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gene therapy, visible in the graph, is exploring approaches to treating diseases such as cystic fibrosis. Sionna Therapeutics is developing small molecules to treat this disease. Its capitalization is a risky bet on its scientific approach and ability to create an effective treatment for all patients with this diagnosis.
Book value capitalization of the company, segment and market as a whole
SION - Book value capitalization of the company Sionna Therapeutics Inc
Sionna Therapeutics' book value represents capital used to fight cystic fibrosis. Its assets at the clinical development stage are primarily cash. The chart shows the financial reserves the company is allocating to research and development of new drugs for this genetic disorder.
SION - Share of the company's book capitalization Sionna Therapeutics Inc within the market segment - Dna
Sionna Therapeutics, a biotechnology company, focuses on the treatment of cystic fibrosis. Its share of the sector's assets consists of R&D laboratories. Currently, the company is investing in science and intellectual property development, which forms the foundation for future therapeutic breakthroughs.
Market segment balance sheet capitalization - Dna
Sionna Therapeutics is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Sionna focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Sionna Therapeutics is a biotechnology company focused on developing novel treatments for cystic fibrosis. Its book value represents capital raised to fund preclinical and clinical trials of its innovative drug candidates.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company. Its book value is its cash. Its market capitalization is a premium to this cash, reflecting investor confidence in the success of its clinical programs in the treatment of cystic fibrosis.
Market to book capitalization ratio in a market segment - Dna
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Its value is almost entirely dependent on the success of its scientific developments. This chart demonstrates the high market valuation of its intellectual property and clinical trial prospects compared to its modest tangible assets.
Market to book capitalization ratio for the market as a whole
Sionna Therapeutics is a biotech company developing new approaches to treating cystic fibrosis. Compared to average market valuations, as shown in this chart, its high premium is based solely on the scientific potential of its research. Investors are betting on the possibility of creating a best-in-class drug.
Debts of the company, segment and market as a whole
SION - Company debts Sionna Therapeutics Inc
Sionna Therapeutics is a clinical-stage biotech company focused on treating cystic fibrosis. Drug development is a lengthy and expensive process. The company relies entirely on external capital to fund research and trials. This chart shows how Sionna manages its financial resources to advance its drug candidates through the development stages.
Market segment debts - Dna
Sionna Therapeutics is a clinical-stage biotech company focused on treating cystic fibrosis. It has no commercial products and is entirely equity-funded. Debt is unlikely at this stage. This chart shows its balance sheet, comprised of cash and R&D expenses.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sionna Therapeutics Inc
Sionna Therapeutics is a biotech company developing drugs for cystic fibrosis. This chart shows its financial structure. For a company in clinical trials and with no revenue, any level of debt is a risk. Equity financing is a safer strategy while waiting for results.
Market segment debt to market segment book capitalization - Dna
Sionna Therapeutics is a biotech company focused on developing treatments for cystic fibrosis. Drug development in this field is a long and capital-intensive process. This chart shows the overall debt burden in the DNA research and biotech sector. It allows one to assess how Sionna finances its clinical programs compared to industry norms.
Debt to book value of all companies in the market
Sionna Therapeutics Inc. is a biotech company working on a treatment for cystic fibrosis. Being in the preclinical stage, it relies entirely on venture capital and equity funding. This chart shows that traditional debt markets are closed to such risky projects, highlighting the importance of investor confidence in its scientific potential for further funding.
P/E of the company, segment and market as a whole
P/E - Sionna Therapeutics Inc
For Sionna Therapeutics, a biotech company working on a treatment for cystic fibrosis, the P/E ratio is meaningless. The company has no products on the market and, therefore, no profit. Any values on this chart are random. Investors evaluate solely the scientific potential of its developments and the chances of success in clinical trials.
P/E of the market segment - Dna
Sionna Therapeutics is a preclinical-stage biotech company focused on developing new treatments for cystic fibrosis, a rare genetic disorder. This chart shows the average valuation for the biotech sector, reflecting investor sentiment toward high-risk scientific developments that could lead to breakthrough drugs.
P/E of the market as a whole
Sionna Therapeutics (privately held, ticker symbol SION may be misleading) is a biotech company developing drugs to treat cystic fibrosis. Its valuation is a bet on developing a best-in-class drug for this disease. It is not tied to the overall economic sentiment reflected in this chart, but depends solely on clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company focused on developing new treatments for cystic fibrosis, a rare genetic disorder. The company's future depends on the success of its clinical programs. This chart reflects investors' confidence in Sionna's scientific approach and the potential of its drugs, estimating its current value based on future revenue projections.
%20P%2FE%20Sionna%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sionna-Therapeutics-Inc&v=1772702315928 "Chart of the company's future (projected) P/E Sionna Therapeutics Inc")
Future (projected) P/E of the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis that target the underlying cause of the disease. The chart reflects average profitability expectations for the biotech sector. SION's position relative to this benchmark reflects investors' bet that its scientific approach will deliver superior results to existing therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772702315929 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Sionna Therapeutics is a biotech company developing treatments for cystic fibrosis. The valuation of such companies depends on scientific breakthroughs and their ability to attract capital. This chart shows the overall investment climate. In a favorable market environment filled with optimism, companies like Sionna have a better chance of securing funding for their research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702315933 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sionna Therapeutics Inc
Sionna Therapeutics is a preclinical biotechnology company focused on developing treatments for cystic fibrosis. Its financials currently consist solely of research and development (R&D) expenses. Potential profitability is entirely dependent on the successful development and commercialization of a new drug.
Profit of companies in the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis using approaches based on the disease's genetics. Its success depends on the results of clinical trials. The data in the graph reflects the overall profitability of its segment, demonstrating how successfully the sector as a whole is progressing in the development and commercialization of gene therapy.
Overall market profit
Sionna Therapeutics is a biotech company working on a cure for cystic fibrosis. Its operations require significant investment in research and development. The overall economic situation, as shown in this chart, directly impacts its ability to raise capital. During periods of growth, investors are more willing to fund long-term, high-risk projects with high potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company focused on developing new treatments for cystic fibrosis. Future profits are entirely dependent on the success of its research and clinical trials. This chart reflects analysts' speculative expectations regarding the potential of Sionna's therapeutic approach in the competitive field of cystic fibrosis treatment.
%20profit%20of%20the%20company%20Sionna%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sionna-Therapeutics-Inc&v=1772702315936 "Graph of future (projected) profit of the company Sionna Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis, a rare genetic disorder. Its future depends on the success of clinical trials and potential drug approvals. This chart reflects profitability projections for the entire biotech sector, providing context for assessing Sionna's risks and prospects in this complex field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772702315937 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Sionna Therapeutics is a biotechnology company developing treatments for cystic fibrosis. Currently, its value is determined solely by scientific progress and clinical trial results. General economic forecasts, such as those shown in this chart, do not directly impact the company's operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702315939 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sionna Therapeutics Inc
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Given that it is in clinical development, its revenue is minimal. This chart shows the enormous value the market is placing on the potential success of its drugs. Its performance depends entirely on news about research and trials.
P/S market segment - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis. Future revenue depends on the success of clinical trials and the drug's market launch. This biotech chart compares investor expectations for Sionna's scientific platform with those of other companies working on breakthrough treatments.
P/S of the market as a whole
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis. The company aims to create a therapy that will benefit a wider range of patients. While in clinical trials, its valuation depends on expectations of future success. This chart helps understand how the market values such research-intensive projects.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sionna Therapeutics Inc
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis, a rare genetic disorder. The company's future depends on the success of its clinical programs. This chart shows how investors view Sionna's scientific potential, betting that its innovative approach will lead to the development of a sought-after treatment.
%20P%2FS%20Sionna%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sionna-Therapeutics-Inc&v=1772702315942 "The graph of the company's future (projected) P/S Sionna Therapeutics Inc")
Future (projected) P/S of the market segment - Dna
Sionna Therapeutics is a clinical-stage biotechnology company focused on developing highly effective small-molecule therapies for the treatment of cystic fibrosis. The company's valuation reflects the company's hopes that its innovative approach will enable therapies to be developed for a broader range of patients than existing drugs from market leader Vertex.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772702315943 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Sionna Therapeutics Inc. is a preclinical biotech company focused on treating cystic fibrosis. Its value reflects expectations of a future scientific breakthrough. This chart reflects revenue projections for existing businesses, while Sionna's represents the potential to create entirely new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702315944 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company developing new treatments for cystic fibrosis. Currently in preclinical and early clinical trials, the company has no commercial products, so its revenue, if shown in the graph, may be related to grants or early partnerships.
Sales of companies in the market segment - Dna
Sionna Therapeutics (SION) is a biotech company focused on developing highly effective drugs for the treatment of cystic fibrosis. It strives to create therapies that will help as many patients with this rare genetic disorder as possible. This figure reflects revenue from the DNA research sector, where Sionna is working on breakthrough solutions.
Overall market sales
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Its success depends on scientific breakthroughs, but the overall economic situation, reflected in the chart, plays a role in its funding. During periods of economic growth, investors are more inclined to invest in long-term and risky projects, such as drug development.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company focused on developing new treatments for cystic fibrosis. Its future revenue is entirely dependent on the results of clinical trials and potential approval of its drugs. This chart reflects analyst expectations, which assess the scientific potential and commercial prospects of Sionna's developments in this area.
%20sales%20of%20the%20company%20Sionna%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sionna-Therapeutics-Inc&v=1772702315949 "Schedule of future (projected) sales of the company Sionna Therapeutics Inc")
Future (projected) sales of companies in the market segment - Dna
Sionna Therapeutics is a biotech company developing drugs to treat cystic fibrosis. This forecast chart reflects the potential future revenue from their pipeline of drug candidates. This is an analyst's perspective on the commercial prospects of their innovative approaches to treating this genetic disorder.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772702315951 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Sionna Therapeutics is a clinical-stage biotechnology company focused on developing new treatments for cystic fibrosis. Its value is determined by the potential of its scientific developments. This graph, reflecting overall market conditions, influences the availability of capital and investor willingness to fund long-term research into rare diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702315952 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sionna Therapeutics Inc
Sionna Therapeutics is a biotechnology company focused on developing new treatments for cystic fibrosis, a rare genetic disorder. Current financial performance reflects significant investments in research and development. The chart shows profitability during preclinical and clinical trials, the success of which determines future profitability.
Market segment marginality - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis. This chart reflects its operating expenses during preclinical and clinical trials. This metric is important for investors to assess how effectively the company is managing its capital as it works to develop a cure.
Market marginality as a whole
Sionna Therapeutics is a biotech company working on a treatment for cystic fibrosis. Its valuation and ability to continue research depend on raising capital. This total return chart reflects the investment climate. During periods of high margins and market optimism, investors are more willing to fund early-stage companies like Sionna.
Employees in the company, segment and market as a whole
Number of employees in the company Sionna Therapeutics Inc
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Its small but growing team consists of leading scientists. The staff increase, reflected in this chart, signals the successful progress of its drug candidates through preclinical and early clinical development.
Share of the company's employees Sionna Therapeutics Inc within the market segment - Dna
Sionna Therapeutics is a biotech company focused on developing new treatments for cystic fibrosis. At the clinical trial stage, its most important asset is its scientific team. This chart reflects the scale of the company's human resources dedicated to combating this rare genetic disease, a measure of its research efforts.
Number of employees in the market segment - Dna
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. This chart, which shows employment in genetic research, demonstrates the overall scientific progress in this field. For Sionna, the growing number of specialists indicates an expanding pool of talent and knowledge needed to develop their innovative approaches to treating this rare disease.
Number of employees in the market as a whole
Sionna Therapeutics is a company focused on treating cystic fibrosis. Its hiring of scientists is based solely on research milestones and clinical progress. It operates in a highly specialized niche, seeking top-notch talent from the general pool of professionals represented in this data.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sionna Therapeutics Inc (SION)
Sionna Therapeutics is a biotech company focused on developing drugs to treat cystic fibrosis. Its entire business is built on cutting-edge scientific research and intellectual property. This metric clearly illustrates how the market values the potential of scientific discoveries, where enormous future value is created by a small team of highly skilled scientists.
%20of%20the%20company%20Sionna%20Therapeutics%20Inc%20(SION)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sionna-Therapeutics-Inc-SION&v=1772702315972 "Chart of market capitalization per employee (in thousands of dollars) of the company Sionna Therapeutics Inc (SION)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Its market capitalization is based on the potential of its scientific developments. This chart shows the high future value the market places on the work of each scientist who could create a new generation of drugs for thousands of patients.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772702315973 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. The chart reflects the company's early-stage scientific potential. The company's entire value is derived from the hopes for its developments. This indicator demonstrates the value the market places on the research and expertise of each scientist on the team working to solve a complex medical problem.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702315973 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sionna Therapeutics Inc (SION)
Sionna Therapeutics is a preclinical biotech company focused on cystic fibrosis. The company has no revenue yet, let alone profit. This graph will show a negative value—the loss (investment in R&D) per scientist. This reflects the intensity of the work being done to develop a potentially breakthrough drug.
%20Chart%20Sionna%20Therapeutics%20Inc%20(SION)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sionna-Therapeutics-Inc-SION&v=1772702315975 "Company Profit Per Employee (in thousands of dollars) Chart Sionna Therapeutics Inc (SION)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. It's another preclinical R&D company. This chart shows the company's loss per employee, not its profit. It reflects how much capital the company spends on each scientist per year to develop a new generation of drugs for this complex disease.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772702315975 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Sionna Therapeutics is a biotech company focused on developing drugs for cystic fibrosis. It's another example of a company in the R&D stage. Its entire focus is on scientific research and clinical trials. There is no profit. This graph demonstrates that employee performance in biotech can't be measured by standard metrics; here, every employee is an investment in a potential breakthrough drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702315976 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sionna Therapeutics Inc (SION)
Sionna Therapeutics is a biotech company focused on treating cystic fibrosis. Currently in preclinical and early clinical trials, it has no commercial products. This graph would show zero revenue, which is typical for R&D companies whose value is determined by the potential of their scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sionna-Therapeutics-Inc-SION&v=1772702315978 "Sales chart per company employee Sionna Therapeutics Inc (SION)")
Sales per employee in the market segment - Dna
Sionna Therapeutics (SION) is a biotech company developing new treatments for cystic fibrosis. This metric reflects the average revenue per employee in the segment. For a clinical-stage company, it helps investors compare its operating efficiency and labor cost structure with other biotech companies.
Sales per employee for the market as a whole
Sionna Therapeutics (SION) is a biotech company focused on treating cystic fibrosis by targeting the underlying cause of the disease. This is a very complex area of R&D. Like other companies in the preclinical or early clinical stages, Sionna likely lacks significant revenue. This metric reflects investment in research staff. Investors in this case are assessing the potential for future breakthroughs rather than current revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Sionna Therapeutics Inc (SION)
Sionna Therapeutics (SION) is a clinical-stage biotech company developing treatments for cystic fibrosis. It's a complex market already dominated by large players. This chart reflects bearish sentiment. The high level of short positions suggests investors doubt SION's ability to develop a drug significantly more effective than existing ones. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sionna-Therapeutics-Inc-SION&v=1772702315981 "Short Shares Chart for the Company Sionna Therapeutics Inc (SION)")
Shares shorted by market segment - Dna
Sionna is a biotech company developing a new generation of drugs for the treatment of cystic fibrosis, attempting to surpass the market leader (Vertex). This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotechs challenging established giants.
Shares shorted by the overall market
Sionna Therapeutics is a clinical-stage biotech company working on cystic fibrosis. Its survival is entirely dependent on access to capital markets to fund R&D. This indicator of market pessimism is an existential threat. Rising fears mean the window for raising capital is closing, jeopardizing its research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sionna Therapeutics Inc (SION)
Sionna Therapeutics (SION) is a clinical-stage biotech focused on developing new treatments for cystic fibrosis. They are striving to create a best-in-class drug. This chart measures hype. It shows "overbought" (above 70) during positive clinical trial data or "oversold" (below 30) during periods of high uncertainty.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sionna-Therapeutics-Inc-SION&v=1772702315986 "RSI 14 indicator chart for the company's stock Sionna Therapeutics Inc (SION)")
RSI 14 Market Segment - Dna
Sionna Therapeutics (SION) is a biotech company developing new treatments for cystic fibrosis, targeting the majority of patients with the disease. This chart tracks the collective sentiment in the DNA/RNA therapeutics sector. It helps investors understand whether the entire biotech segment is overhyped or oversold amid setbacks.
RSI 14 for the overall market
Sionna Therapeutics (SION) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SION (Sionna Therapeutics Inc)
Sionna Therapeutics is a biotech company focused on developing a new class of drugs for the treatment of cystic fibrosis, targeting the underlying cause of the disease. This chart reflects the collective opinion of experts on the fair 12-month share price of SION, based on R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SION-Sionna-Therapeutics-Inc&v=1772702315995 "A chart showing analyst consensus forecasts for the expected stock price. SION (Sionna Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price SION (Sionna Therapeutics Inc)
Sionna Therapeutics is a preclinical biotech focused on treating cystic fibrosis (CF). They are working to develop a best-in-class drug that will treat 90% of patients with the disease. This chart reflects analysts' very early and speculative expectations regarding their science and competition with Vertex.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SION-Sionna-Therapeutics-Inc&v=1772702316004 "A chart showing the difference between the consensus forecast and the actual stock price. SION (Sionna Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Dna
Sionna Therapeutics is a biotech company striving to develop a best-in-class drug for the treatment of cystic fibrosis (CF), targeting patients who have failed existing therapies. This chart shows general expectations for the DNA technology sector, reflecting whether experts believe new breakthroughs are possible in the CF market.
Analysts' consensus forecast for the overall market share price
Sionna Therapeutics is a biotech company developing a new class of drugs for the treatment of cystic fibrosis, targeting the majority of patients. This chart shows the overall risk appetite. For Sionna, as a clinical-stage company, overall market optimism is important for raising the capital needed to compete with the giants in this field.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sionna Therapeutics Inc
Sionna Therapeutics is a biotech company challenging giant Vertex in the multibillion-dollar cystic fibrosis (CF) market. Their goal is to create a best-in-class drug (a combination of small molecules) to treat this rare genetic disease. This chart is an assessment of their ambitious R&D program and reflects investor expectations for their clinical data in this challenging race.
AKIMA Market Segment Index - Dna
Sionna Therapeutics (SION) is a clinical-stage biotech focused on cystic fibrosis (CF) (a competitor of Vertex); the company is developing a new generation of small molecules to treat this disease. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (CF) R&D focus (SION) differentiate it from the average pharma company?
The AKIM Index for the overall market
Sionna Therapeutics is a biotech company developing small molecules for the treatment of cystic fibrosis. It aims to restore the function of the CFTR protein. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific company, competing in a complex therapeutic field, compares to overall economic trends.
